Skip to content
Screener

Vertex Pharmaceuticals VRTX Share Repurchase Program - Amount Remaining

Share Repurchase Program - Amount Remaining at other companies

AbbVie logo
AbbVieABBV
——

Other financials

Income statement

See full
Revenue$3.3B+12.5%
Gross profit$2.8B+11.2%
Operating income$1.2B+8.3%
Net income$1.1B+6.5%
EPS (diluted)$4.31+8.0%

Balance sheet

See full
Cash & equivalents$7.9B+57.6%
Total debt$2.0B+29.5%
Total equity$20.2B+17.9%
Total assets$27.4B+14.1%

Cash flow

See full
Operating cash flow$1.4B+74.4%
CapEx$133.4M+228%
Free cash flow$1.3B+66.4%

Valuation

See full
Market cap$125.73B+31.0%
Enterprise value$119.86B+29.5%
P/E28.5×—
P/S10×+1.6×

Profitability

See full
Gross margin86%-0.1pp
Operating margin38%—
Net margin35%—
FCF margin30.4%+20.2pp

Returns & leverage

See full
Return on equity23.5%—
Debt / equity0.1×0.0×
Current ratio3.2×+0.7×

Where this comes from

Reported directly by Vertex Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1.

The source filing: Vertex Pharmaceuticals’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:08 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0000875320-26-000173

million, respectively. As of March 31, 2026, we had $3.0 billion remaining available under the 2025 Share Repurchase

Item 1. Financial Statements (unaudited)

FAQ

What is Vertex Pharmaceuticals's share repurchase program - amount remaining?
Vertex Pharmaceuticals (VRTX) reported share repurchase program - amount remaining of $3B in Q1 2026.
How has Vertex Pharmaceuticals's share repurchase program - amount remaining changed year-over-year?
Vertex Pharmaceuticals's share repurchase program - amount remaining increased by 211.1% year-over-year, from $964.4M to $3B.

Ask your AI about Vertex Pharmaceuticals's share repurchase program - amount remaining.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude